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pT3/4 and pN+ in a preoperative model including age, gen-
der, tumor multifocality, tumor localization and the Eastern 
Cooperative Oncology Group Performance Status. In a mul-
tivariable Cox regression model adjusted for features sig-
nificant in univariable analysis, categorized and continuous 
CRP levels were both independent predictors for RFS [hazard 
ratio (HR) 1.18, p = 0.050; HR 1.03, p = 0.012] and DSS (HR 
1.61, p = 0.026; HR 1.06, p = 0.001). Continuous CRP was an 
independent predictor for ACS (HR 1.05, p = 0.036).  Conclu-
sions: Elevated preoperative CRP is significantly associated 
with aggressive tumor biology and an independent predic-
tor for poor survival after RNU. Preoperative serum CRP rep-
resents an easily obtainable and cost-effective marker in 
UTUC and may help in counseling patients with regard to 
operative management and/or adjuvant or neoadjuvant 
therapies.  © 2014 S. Karger AG, Basel 
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 Abstract 
 Objective: To investigate the impact of preoperative serum 
C-reactive protein (CRP) on clinicopathological features and 
prognosis in patients with upper tract urothelial cancer 
(UTUC) after radical nephroureterectomy (RNU).  Patients 
and  Methods: Data of 265 patients from three German cen-
ters who underwent RNU for UTUC without neoadjuvant 
chemotherapy between 1990 and 2012 were evaluated. 
Mean follow-up was 37 months (interquartile range 9–48). 
CRP was analyzed as a categorical and continuous variable 
for the prediction of recurrence-free survival (RFS), disease-
specific survival (DSS) and all-cause survival (ACS) using uni- 
and multivariate Cox regression analyses.  Results: The opti-
mal cutoff for CRP was calculated by the Youden index at 
0.90 mg/dl. Elevated CRP was significantly associated with 
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 Introduction 
 Upper tract urothelial carcinoma (UTUC) accounts 
for 5% of all urothelial cancers  [1] and thus represents an 
uncommon and rare malignancy  [2] . Radical nephroure-
terectomy (RNU) with bladder cuff excision remains the 
gold standard for treatment of UTUC  [3] . Unfortunately, 
approximately 60% of UTUCs are diagnosed at an ad-
vanced tumor stage, resulting in a poor overall prognosis 
 [3] . 
 Several predictors of outcomes of UTUC have been 
investigated  [4–8] . However, data using serum biomark-
ers are limited. The biomarker C-reactive protein (CRP) 
is an easily obtainable serum laboratory marker for in-
flammation used commonly in clinical practice. Indeed, 
elevation of CRP has already been shown to predict out-
comes in renal cell, bladder and prostate cancer  [9, 10] . In 
UTUC, elevated preoperative serum CRP (sCRP) has 
been found to be an independent predictor of outcome 
following RNU  [11–14] . 
 The aim of this retrospective multi-institutional study 
was therefore threefold. First, we sought to evaluate the 
association between clinico-pathological features and 
preoperative sCRP. Second, the impact of preoperative 
sCRP on predicting advanced tumor stage (pT3/T4 or 
positive lymph nodes) was assessed. Third, we evaluated 
the ability of sCRP to predict recurrence and survival in 
patients with UTUC following RNU.
 Patients and Methods 
 Patient Selection and Data Collection 
 This retrospective study involved three German academic cen-
ters (Hamburg, Tübingen and Regensburg). All centers agreed to 
transfer data into a common computerized database. Prior to study 
initiation, appropriate data-sharing agreements and institutional 
review board approval were obtained from each participating cen-
ter. Data from a total of 348 patients from 1990 to 2012 with a his-
tory of UTUC treated with RNU without evidence of distant me-
tastases were included in the study. Patients with a history of radi-
cal cystectomy for the treatment of muscle-invasive or high-risk 
non-muscle-invasive bladder cancer (n = 11), with missing clinical 
data or follow-up (n = 42), with missing preoperative sCRP (n = 29) 
or treated with neoadjuvant chemotherapy (n = 1) were excluded 
from the study. A total of 265 patients who underwent RNU for 
UTUC had complete datasets and formed the study cohort. 
 Prior to RNU, diagnostic ureterorenoscopy (6%), ureterore-
noscopy with biopsy (56%) or imaging with selective upper uri-
nary tract cytology (38%) was performed. RNU was performed as 
described previously  [15, 16] . The kidney, entire ureteral length 
and adjacent segment of the bladder cuff were removed. Lymph-
adenectomy (hilar, regional) was performed in patients with suspi-
cious lymph nodes on preoperative CT findings or with suspicious 
intraoperative findings and was performed at the discretion of the 
attending physician. The synchronous presence of two or more 
pathologically confirmed tumors in any location (renal pelvicaly-
ceal system, ureter or both) was defined as tumor multifocality 
 [17] . No patient received preoperative systemic chemotherapy or 
perioperative radiotherapy. Adjuvant chemotherapy was adminis-
tered in 47 patients (16.7%) at the treating physician’s discretion. 
Systemic chemotherapy was platinum-based in 89% of the cases. 
 Preoperative measurement of sCRP was routinely performed 
up to 3 days prior to RNU. All patients were preoperatively 
screened for urinary tract infections using a dipstick test and/or 
urinary cultures. No patient with an active infection and/or fever 
(>38.0  °  C) was included in the study. No patient had accompany-
ing hematologic disorders, chronic inflammatory or autoimmune 
diseases, or had received prior steroid therapy. Due to the rela-
tively short half-life of sCRP (approximately 24 h) it seems un-
likely that preoperative manipulations would have affected sCRP 
at the time of RNU.
 Pathologic Evaluation 
 All surgical specimens were processed according to standard 
pathologic procedures and analyzed by experienced genitourinary 
pathologists at their respective centers. Pure variant histology was 
not observed in any patient  [16] . All tumors were staged according 
to the 2010 American Joint Committee on Cancer TNM classifica-
tion  [18] . Tumor grading was performed according to the 1998 
World Health Organization/International Society of Urological 
Pathology consensus classification  [19] . Histopathologic evalua-
tion included concomitant carcinoma in situ, tumor architecture 
(papillary or sessile according to the predominant feature of the 
index lesion  [20] ) and lymphovascular invasion (LVI; defined as 
the presence of tumor cells within an endothelium-lined space 
without underlying muscular walls  [21] ). 
 Follow-Up 
 Follow-up was performed according to protocols established at 
each respective center but followed current guideline recommen-
dations  [1] . In general, patients were followed every 3–4 months for 
the first 2 years after RNU, every 6 months in years 3–5 and annu-
ally thereafter. Follow-up included a history and physical examina-
tion, urinary cytology and cystoscopic evaluation of the urinary 
bladder. CT of the abdomen including evaluation of the contralat-
eral upper urinary tract and chest radiography were performed ev-
ery 6 months or when clinically indicated. Bone or brain scans, 
thorax CT scans or magnetic resonance imaging were performed 
only when clinically indicated. Tumor relapse in the operative field, 
regional lymph nodes and/or distant metastasis was defined as dis-
ease recurrence. Urothelial carcinoma in the bladder or contralat-
eral upper tract were viewed as metachronous tumors and not doc-
umented as a recurrence. Cause of death was determined by the 
treating physician, by chart review collaborated by death certifi-
cates or by death certificates alone  [22] . To diminish bias in assign-
ing the cause of death, all patients with UTUC listed on their death 
certificate and with documented previous disease progression were 
listed as having died of their UTUC. Perioperative mortality (i.e. 
any death within 30 days of surgery or before discharge) was not 
included for cancer-specific survival analyses. Duration of follow-
up was assessed from the date of surgery until the last follow-up. 
Recurrence-free survival (RFS), disease-specific survival (DSS) and 
all-cause survival (ACS) were the end points of the study. 
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 Statistical Analysis 
 The Youden index was applied to identify the optimal cutoff 
for preoperative sCRP levels. The Kolmogorov-Smirnov test was 
applied to investigate the normal distribution of continuous vari-
ables. Continuous variables are presented as means with standard 
deviations or medians with interquartile ranges depending on the 
type of distribution. The Wilcoxon rank sum test (Mann-Whitney 
U test for two categories) and the Kruskal-Wallis test (three or 
more categories) were applied for nonnormally distributed vari-
ables. Comparison between categorical variables was performed 
using Fisher’s exact test and the χ 2 test.
 The impact of the preoperative features sCRP, age, gender, tu-
mor multifocality, tumor localization and the Eastern Cooperative 
Oncology Group Performance Status (ECOG-PS) on predicting 
advanced-stage disease (pT3/T4 or N1 disease) was analyzed using 
a binary logistic regression analysis. 
 RFS, DSS and ACS rates were estimated using the Kaplan-Meier 
method; the log-rank test was employed to compare survival curves. 
Cox proportional hazards regression models were performed to as-
sess the influence of clinicopathological parameters on disease re-
currence and mortality. The impact of categorized and continuous 
preoperative sCRP in multivariable models was assessed using the 
area under the curve (AUC) of the receiver operator characteristic. 
Evaluation of AUC values (c-indices) for estimation of the predic-
tive accuracy (PA) was performed according to Harrell et al.  [23] . 
The c-indices were compared with the Mantel-Haenszel test.
 Statistical analyses were performed with SPSS Statistics ® 20 
(SPSS, IBM Corp., Armonk, N.Y., USA) and R (version 3.0.0, The 
R Foundation for Statistical Computing, Vienna, Austria). Report-
ed p values are two-sided with the statistical significance level set 
at p  ≤ 0.05.
 Results 
 The descriptive  characteristics of the study population 
are displayed in  table 1 . The optimal cutoff for the preop-
erative sCRP level was defined by the Youden index as 
0.90 mg/dl. sCRP levels >0.90 mg/dl were classified as be-
ing elevated. Our study group comprised a total of 149 
patients (44.8%) with sCRP levels >0.90 mg/dl and 116 
patients (56.2%) with sCRP levels  ≤ 0.90 mg/dl. The mean 
age in the two groups was 69.8 and 67.7 years (p = 0.060), 
respectively. Distribution of gender was equal in both 
groups (p = 0.550). Patients with sCRP levels >0.90 mg/
dl presented more commonly with advanced pT stages 
pT3/4 (53.7 vs. 25.9%; p < 0.001), grade G3 tumors (66.4 
vs. 54.3%; p < 0.001), lymph node involvement (30.2 vs. 
12.1%; p < 0.001) and LVI (26.4 vs. 11.5%; p = 0.002). Ses-
sile tumors were more commonly observed in patients 
with sCRP levels >0.90 mg/dl (34.2 vs. 13.8%; p < 0.001). 
No further significant CRP level-specific differences were 
seen when comparing ECOG-PS, tumor multifocality, 
tumor localization and administration of adjuvant che-
motherapy.
 Table 1. Clinicopathological characteristics of 265 UTUC patients 
treated with RNU according to sCRP levels
Variable CRP p
≤0.90 mg/dl >0.90 mg/dl
Number 116 (56.2) 149 (44.8)  
Age at time of RNU 
(mean ± SD), years
67.7 ± 9.85 69.8 ± 8.85 0.060
Gender   0.550
Male 74 (63.8) 95 (63.8)  
Female 42 (36.2) 54 (36.2)  
ECOG-PS   0.442
0 53 (21.6) 66 (26.9)  
≥1 50 (20.4) 76 (31.0)  
Tumor localization   0.210
Pelvicalyceal 57 (39.3) 88 (60.7)  
Ureter 33 (46.5) 38 (53.5)  
Both 26 (53.1) 23 (46.9)  
Tumor multifocality   0.103
Single tumor 69 (59.9) 105 (70.5)  
≥2 tumors 47 (40.5) 44 (29.5)  
Pathologic tumor stage   <0.001
Ta–T1 60 (51.7) 46 (30.9)  
T2 26 (22.4) 23 (15.4)  
T3 26 (22.4) 76 (51.0)  
T4 4 (3.4) 4 (2.7)  
Advanced tumor stage
pT3/T4
30 (25.9) 80 (53.7) <0.001
Tumor grade   <0.001
1 12 (10.3) 31 (20.8)  
2 41 (35.3) 19 (12.8)  
3 63 (54.3) 99 (66.4)  
Lymph node involvement   <0.001
pNX or pN0 102 (87.9) 104 (69.8)  
pN+ 14 (12.1) 45 (30.2)  
LVI  0.002
Present 13 (11.5) 39 (26.4)  
Absent 100 (88.5) 109 (73.6)  
Tumor architecture   <0.001
Papillary 100 (86.2) 98 (65.8)  
Sessile 16 (13.8) 51 (34.2)  
Adjuvant chemotherapy   0.190
Administered 17 (14.7) 29 (19.5)  
Not administered 99 (85.3) 120 (80.5)  
 Values represent numbers of patients with percentages in pa-
rentheses, except where indicated otherwise.
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 In a binary logistic regression model for the calcula-
tion of the predictive capacity of preoperative features for 
advanced disease, an elevated preoperative sCRP >0.90 
mg/dl was the only independent predictor for pT3/pT4 
[hazard ratio (HR) 3.79, p < 0.001] and pN+ disease (HR 
2.65, p = 0.006) ( table 2 ).
 Mean follow-up was 37 months (interquartile range 
10–48, median 23). During follow-up, disease recurred in 
92 patients (34.7%), 69 patients (26.0%) died of UTUC 
and the rate of all-cause mortality was 49.1% (130 pa-
tients). The 5-year RFS rate was 44% in patients with CRP 
levels  ≤ 0.90 mg/dl and 39% in patients with sCRP levels 
>0.90 mg/dl (p = 0.062;  fig. 1 a). The 5-year DSS rate was 
68% in patients with CRP levels  ≤ 0.90 mg/dl and 51% in 
patients with sCRP levels >0.90 mg/dl (p = 0.005;  fig. 1 b). 
The corresponding 5-year ACS rates were 25 and 13%, 
respectively (p = 0.016;  fig. 1 c).
 In univariable analysis ( table  3 ), ECOG-PS  ≥ 1 (HR 
1.66, p = 0.029), multifocality (HR 1.71, p = 0.11), tumor 
stage (HR 3.99, p < 0.001), tumor grade (HR 2.85, p < 
0.001), lymph node involvement (HR 2.07, p = 0.001), 
LVI (HR 4.16, p < 0.001), tumor architecture (HR 1.87, 
p = 0.005), sCRP >0.90 mg/dl (HR 1.49, p = 0.036) and 
continuous sCRP (HR 1.54, p = 0.004) were significantly 
associated with RFS. ECOG-PS  ≥ 1 (HR 2.17, p = 0.005), 
tumor stage (HR 5.38, p < 0.001), tumor grade (HR 3.24, 
p < 0.001), lymph node involvement (HR 2.74, p = 0.001), 
LVI (HR 4.47, p < 0.001), tumor architecture (HR 2.18, 
p = 0.002), sCRP >0.90 mg/dl (HR 2.07, p = 0.006) and 
continuous sCRP (HR 1.08, p < 0.001) were significantly 
associated with DSS. Age (HR 1.03, p = 0.020), ECOG-PS 
 ≥ 1 (HR 1.55, p = 0.022), tumor stage (HR 2.83, p < 0.001), 
tumor grade (HR 1.89, p = 0.001), lymph node involve-
ment (HR 1.92, p = 0.001), LVI (HR 2.92, p < 0.001), tu-
mor architecture (HR 1.57, p = 0.021), sCRP >0.90 mg/dl 
(HR 1.55, p = 0.017) and continuous sCRP (HR 1.06, p < 
0.001) were significantly associated with ACS.
 In multivariable Cox regression analysis that adjusted 
for significant parameters in univariable analysis ( ta-
ble 3 ), tumor stage (HR 2.61, p = 0.001), LVI (HR 2.70, 
p < 0.001), sCRP >0.90 mg/dl (HR 1.18, p = 0.050) and 
continuous sCRP (HR 1.03, p = 0.012) were independent 
predictors of disease recurrence. The respective c-indices 
of this model with and without inclusion of dichotomized 
and continuous sCRP were 0.728 and 0.714 (PA gain 
1.4%, p = 0.049) and 0.779 and 0.754 (PA gain 2.5%, p = 
0.039). Furthermore, tumor stage (HR 2.60, p = 0.002), 
LVI (HR 2.50, p < 0.001), sCRP >0.90 mg/dl (HR 1.61, 
p = 0.026) and continuous sCRP (HR 1.06, p = 0.001) in-
dependently impacted DSS. The respective c-indices of 
the DSS model with and without inclusion of dichoto-
mized and continuous sCRP were 0.741 and 0.729 (PA 
gain 1.2%, p = 0.044) and 0.744 and 0.726 (PA gain 1.8%, 
p = 0.048). Age (HR 1.03, p = 0.011), tumor stage (HR 
 Table 2. Preoperative binary logistic regression model predicting advanced tumor stage pT3/pT4 and positive 
lymph node involvement in 265 UTUC patients treated with RNU
Variable HR (95% CI) p
Prediction of advanced tumor stage pT3/pT4
Age at RNU (continuous; years) 1.02 (0.98 – 1.05) 0.381
Female gender (reference: male) 1.22 (0.69 – 2.15) 0.487
ECOG-PS ≥1 (reference: ECOG-PS 0) 1.20 (0.68 – 2.20) 0.550
Tumor multifocality (≥2 tumors vs. single tumor) 1.74 (0.77 – 3.93) 0.185
Tumor localization  
Ureteral vs. pelvicalyceal 0.68 (0.35 – 1.32) 0.257
Both vs. pelvicalyceal only 0.47 (0.17 – 1.30) 0.146
Serum CRP level >0.90 mg/dl (reference: ≤0.90 mg/dl) 3.79 (2.11 – 6.80) <0.001
Prediction of positive lymph node involvement
Age at RNU (continuous; years) 1.02 (0.98 – 1.06) 0.394
Female gender (reference: male) 0.95 (0.50 – 1.82) 0.879
ECOG-PS ≥1 (reference: ECOG-PS 0) 1.28 (0.64 – 2.59) 0.481
Tumor multifocality (≥2 tumors vs. single tumor) 1.55 (0.64 – 3.78) 0.332
Tumor localization  
Ureteral vs. pelvicalyceal 0.88 (0.43 – 1.84) 0.740
Both vs. pelvicalyceal only 0.34 (0.10 – 1.14) 0.080
Serum CRP level >0.90 mg/dl (reference: ≤0.90 mg/dl) 2.65 (1.32 – 5.30) 0.006
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 Fig. 1. Kaplan-Meier plots displaying prob-
abilities of RFS ( a ), DSS ( b ) and ACS ( c ) 
according to preoperative sCRP levels in 
265 UTUC patients treated with RNU. 
(For figure 1c see next page.)
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2.37, p < 0.001), LVI (HR 1.91, p = 0.004) and continuous 
sCRP (HR 1.05, p = 0.036) were significant predictors of 
ACS. The respective c-indices of this model with and 
without inclusion of continuous sCRP were 0.706 and 
0.676 (PA gain 3.0%, p = 0.039).
 Discussion 
 The aim of the present study was to analyze the predic-
tive impact of preoperative sCRP levels for patients with 
UTUC treated with RNU. Our findings confirm that pre-
operative sCRP levels have a significant association with 
aggressive tumor biology and poor outcome in UTUC. 
We found that CRP levels were a strong predictor for RFS, 
DSS and ACS, respectively. 
 We could not verify the results of a previous study 
 [14] using a preoperative CRP threshold level of 0.50 mg/
dl as an independent predictor of DSS. These authors 
used this CRP cutoff based on the manufacturing recom-
mendations that a value of <0.50 mg/ml is considered 
normal  [24] . In contrast, we sought to determine the op-
timal cutoff point for sCRP levels. Therefore, we investi-
gated different preoperative sCRP cutoff values in order 
to determine the optimal predictor of RFS, DSS and ACS. 
Our calculations revealed a cutoff of 0.90 mg/dl, as de-
fined by the Youden index.
 Saito et al.  [11] published the first retrospective study 
addressing CRP in UTUC. In their single-center study 
with 130 UTUC patients, 24 patients (18%) had elevated 
preoperative CRP levels of >0.50 mg/dl. Higher tumor 
stage and grade, positive lymph node involvement and 
the presence of LVI were significantly associated with el-
evated CRP levels. In line with our results, the authors 
identified elevated preoperative sCRP levels as an inde-
pendent predictor of both RFS and DSS. However, the 
authors did not evaluate the association between sCRP 
and ACS. In the present study, continuous sCRP inde-
pendently predicted ACS. Stein et al.  [13] found that con-
tinuous sCRP was an independent prognosticator for 
DSS. The authors were able to demonstrate that a CRP 
value >5 mg/l was significantly associated with DSS in 
univariable Cox regression analysis. Unfortunately, no 
data for categorized CRP values were shown in their mul-
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 Table 3.  Uni- and multivariable regression analysis predicting disease recurrence, disease-specific and all-cause mortality in 265 UTUC 
patients treated with RNU
Variable Univariable regression analysis Multivariable regression analysis
HR (95% CI) p value HR (95% CI) p value
Disease recurrence  
Age at RNU (continuous; years) 0.99 (0.98 – 1.02) 0.825 – –
Female gender (ref.: male) 1.81 (0.77 – 1.80) 0.441 – –
ECOG-PS ≥1 (ref.: ECOG-PS 0) 1.66 (1.05 – 2.62) 0.029 1.29 (0.79 – 2.11) 0.301
Tumor multifocality (≥2 tumors vs. single tumor) 1.71 (1.13 – 2.59) 0.011 1.46 (0.91 – 2.34) 0.118
Tumor localization 
Ureteral vs. pelvicalyceal 0.81 (0.50 – 1.33) 0.412 – –
Both vs. pelvicalyceal only 0.72 (0.39 – 1.34) 0.297 – –
pT3/4 (ref.: ≤T2) 3.99 (2.59 – 6.15) <0.001 2.61 (1.51 – 4.50) 0.001
G3 (ref.: G1/G2) 2.85 (1.78 – 4.55) <0.001 1.37 (0.77 – 2.46) 0.284
Lymph node involvement (pN+ vs. pN0/pNX) 2.07 (1.34 – 3.19) 0.001 0.90 (0.52 – 1.58) 0.717
LVI (ref.: negative) 4.16 (2.70 – 6.41) <0.001 2.70 (1.59 – 4.57) <0.001
Tumor architecture (sessile vs. papillary) 1.87 (1.21 – 2.91) 0.005 1.03 (0.59 – 1.81) 0.923
Preoperative serum CRP level
≤0.50 vs. >0.50 mg/dl 1.20 (0.75 – 1.91) 0.451 – –
≤0.90 vs. >0.90 mg/dl 1.49 (0.98 – 2.27) 0.036 1.18 (0.71 – 1.97) 0.050
Continuous 1.54 (1.02 – 1.09) 0.004 1.03 (0.98 – 1.08) 0.012
Disease-specific mortality
Age at RNU (continuous; years) 1.01 (0.98 – 1.04) 0.440 – –
Female gender (ref.: male) 1.10 (0.65 – 1.73) 0.820 – –
ECOG-PS ≥1 (ref.: ECOG-PS 0) 2.17 (1.26 – 3.74) 0.005 1.74 (0.96 – 3.14) 0.066
Tumor multifocality (≥2 tumors vs. single tumor) 1.59 (0.99 – 2.56) 0.060 0.64 (0.33 – 1.24) 0.185
Tumor localization 
Ureteral vs. pelvicalyceal 0.80 (0.46 – 1.41) 0.448 0.70 (0.36 – 1.37) 0.303
Both vs. pelvicalyceal only 0.80 (0.40 – 1.59) 0.521 0.77 (0.30 – 2.01) 0.595
pT3/4 (ref.: ≤T2) 5.38 (2.75 – 10.5) <0.001 2.60 (1.44 – 4.68) 0.002
G3 (ref.: G1/G2) 3.24 (1.84 – 5.68) <0.001 1.57 (0.84 – 2.98) 0.160
Lymph node involvement (pN+ vs. pN0/pNX) 2.74 (1.69 – 4.43) <0.001 1.29 (0.74 – 2.70) 0.371
LVI (ref.: negative) 4.47 (2.75 – 7.28) <0.001 2.50 (1.45 – 4.30) <0.001
Tumor architecture (sessile vs. papillary) 2.18 (1.33 – 3.57) 0.002 1.00 (0.51 – 1.60) 0.740
Preoperative serum CRP level
≤0.50 vs. >0.50 mg/dl 1.39 (0.80 – 2.44) 0.246 – –
≤0.90 vs. >0.90 mg/dl 2.07 (1.24 – 3.46) 0.006 1.61 (0.95 – 2.73) 0.026
Continuous 1.08 (1.04 – 1.11) <0.001 1.06 (1.02 – 1.10) 0.001
All-cause mortality
Age at RNU (continuous; years) 1.03 (1.01 – 1.05) 0.020 1.03 (1.01 – 1.05) 0.011
Female gender (ref.: male) 1.05 (0.73 – 1.52) 0.800 – –
ECOG-PS ≥1 (ref.: ECOG-PS 0) 1.55 (1.06 – 2.25) 0.022 1.18 (0.76 – 1.83) 0.456
Tumor multifocality (≥2 tumors vs. single tumor) 1.27 (0.88 – 1.82) 0.200 – –
Tumor localization 
Ureteral vs. pelvicalyceal 1.00 (0.67 – 1.49) 1.00 – –
Both vs. pelvicalyceal only 0.87 (0.52 – 1.44) 0.581 – –
pT3/4 (ref.: ≤T2) 2.83 (1.90 – 4.21) <0.001 2.37 (1.56 – 3.62) <0.001
G3 (ref.: G1/G2) 1.89 (1.31 – 2.72) 0.001 1.11 (0.73 – 1.70) 0.625
Lymph node involvement (pN+ vs. pN0/pNX) 1.92 (1.33 – 2.79) 0.001 1.13 (0.73 – 1.76) 0.584
LVI (ref.: negative) 2.92 (1.97 – 4.33) <0.001 1.91 (1.22 – 2.98) 0.004
Tumor architecture (sessile vs. papillary) 1.57 (1.07 – 2.31) 0.021 0.87 (0.55 – 1.36) 0.531
Preoperative serum CRP level
≤0.50 vs. >0.50 mg/dl 1.37 (0.91 – 2.06) 0.130 – –
≤0.90 vs. >0.90 mg/dl 1.55 (1.08 – 2.21) 0.017 1.23 (0.84 – 1.80) 0.280
Continuous 1.06 (1.02 – 1.01) <0.001 1.05 (1.02 – 1.09) 0.036
ref. = Reference; pT = pathological tumor stage; G = tumor grading; pN = pathological nodal stage.
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tivariable analysis. In our study, elevated sCRP levels cat-
egorized at 0.90 mg/dl independently influenced both 
RFS and DSS. Tanaka et al.  [14] previously published a 
study subdividing patients into 3 groups according to 
preoperative sCRP values. The authors found that elevat-
ed preoperative sCRP levels significantly impacted on 
both RFS and DSS. Furthermore, they were able to dem-
onstrate in a subgroup analysis that postoperative nor-
malization of CRP levels was associated with improved 
outcomes  [14] . In order to substantiate this finding, we 
also performed a subgroup analysis in our patients who 
showed an elevated preoperative sCRP level and postop-
erative normalization of the CRP levels (n = 143). How-
ever, we could not find any impact of sCRP on RFS, DSS 
and ACS in this scenario within the present study. In ad-
dition, the findings of our preoperative model for predic-
tion of an advanced pathological tumor stage of pT3/pT4 
and positive lymph node involvement revealed sCRP as 
an independent predictor for both of these end points. To 
the best of our knowledge, our findings are currently the 
first to address this issue. 
 Although several reports describe the independent as-
sociation of elevated preoperative sCRP levels with poor-
er outcomes in various malignancies, the reasons for this 
finding remain unclear  [25] . Three hypotheses have been 
postulated to date. First, elevated CRP levels may reflect 
a tumor’s ability to produce large amounts of proinflam-
matory cytokines, notably interleukin-6, which may con-
tribute to tumor growth  [26, 27] . Secondly, CRP might 
reflect an altered immune function, which consequently 
leads to tumor proliferation and dissemination  [28, 29] . 
Third, proinflammatory cytokines are able to stimulate 
endothelial cells, fibroblasts and anti-inflammatory cells 
directly within the tumor, thereby enhancing angiogen-
esis, invasion, metastases and immune suppression  [30, 
31] . Influencing these pathways has been considered in 
novel therapeutic approaches  [32] . Finally, elevated sCRP 
levels are associated with unintended weight loss and tis-
sue destruction that might also contribute to a poorer 
DSS  [33] .
 Although our study is one of the largest investigating 
the impact of sCRP levels on UTUC outcomes, we recog-
nize some limitations of this retrospective study. We were 
unable to adjust for the possible influence of numerous 
surgeons at each institution with differing preferences, 
experience and techniques. The absence of a standard 
lymphadenectomy as well as differences in the lymph 
node counts may also bias our findings. We also cannot 
exclude differences between pathologists, as a central pa-
thology review was not conducted. However, all surgeons 
and pathologists operated at centers experienced in the 
management of UTUC. Finally, sCRP levels may have 
been influenced by other underlying disease processes, 
which were not identified preoperatively. We were also 
unable to account for differences between the time of the 
initial CRP blood draw and subsequent RNU. Despite 
these limitations, this represents one of the largest multi-
institutional studies investigating the role of CRP in 
UTUC. However, our findings need to be verified in pro-
spective, randomized studies. 
 Conclusion 
 In conclusion, preoperative elevation of the nonspe-
cific inflammatory biomarker sCRP was significantly as-
sociated with adverse tumor biology and poor outcome 
after RNU. Our results confirm previous findings estab-
lishing this biomarker as a simple and cost-effective se-
rum biomarker for the preoperative prediction of ad-
vanced tumor stage and poorer survival in UTUC. CRP 
may further help identify high-risk patients and guide op-
erative management and decision-making with regard to 
neoadjuvant or adjuvant therapies.
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